Figure 17, Breast abnormalities (other than cancer) in trials of raloxifene versus placebo
Carolyn Crandall(University of California, Los Angeles), Paul G Shekelle(VA Greater Los Angeles Healthcare System), Marika J Suttorp, Roberta Shanman(RAND Corporation), Beth Roth, Sydne J Newberry, Brett Ewing, Allison Diamant(RAND Corporation), Aneesa Motala(University of Southern California), Yee-Wei Lim(RAND Corporation), Martha Timmer(RAND Corporation), Walid F. Gellad(University of Pittsburgh)
Unknown
March 1, 2012
Cited by 0
Related Papers
Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated?
|PubMed|2001|599
The effectiveness of computerized order entry at reducing preventable adverse drug events and medication errors in hospital settings: a systematic review and meta-analysis
|Systematic Reviews|2014|343
Patients' Global Ratings of Their Health Care Are Not Associated with the Technical Quality of Their Care
|Annals of Internal Medicine|2006|294
Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures
|Annals of Internal Medicine|2014|256
The Quality of Pharmacologic Care for Vulnerable Older Patients
|Annals of Internal Medicine|2004|240